NextCure (NXTC) Depreciation & Amortization (CF) (2018 - 2026)
NextCure (NXTC) posted quarterly Depreciation & Amortization (CF) of $283000.0 for Q1 2026, down 56.73% year-over-year from $654000.0 in Q1 2025, and down 22.47% quarter-over-quarter from $365000.0 in Q4 2025.
NextCure (NXTC) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
NextCure's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $283000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 56.73% year-over-year to $283000.0; the TTM figure through Mar 2026 stood at $1.8 million (down 34.37% YoY), while the FY2025 annual figure was $2.2 million, down 24.66% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $283000.0, down from $365000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.1 million in Q1 2022, with the low at $283000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $790000.0 (2024), against an average of $774588.2.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 259.17% in 2022, then slumped 56.73% in 2026.
- NextCure's Depreciation & Amortization (CF) stood at $983000.0 in 2022, then declined by 14.55% to $840000.0 in 2023, then declined by 15.6% to $709000.0 in 2024, then sank by 48.52% to $365000.0 in 2025, then dropped by 22.47% to $283000.0 in 2026.
- Business Quant data shows NXTC's Depreciation & Amortization (CF) at $283000.0 in Q1 2026, $365000.0 in Q4 2025, and $533000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 272,000.00 |
| Jun 30, 2026 | 272,000.00 |
| Mar 31, 2026 | 283,000.00 |
| Mar 31, 2026 | 283,000.00 |
| Dec 31, 2025 | 365,000.00 |
| Dec 31, 2025 | 365,000.00 |
| Sep 30, 2025 | 533,000.00 |
| Sep 30, 2025 | 533,000.00 |
| Jun 30, 2025 | 633,000.00 |
| Jun 30, 2025 | 633,000.00 |
| Mar 31, 2025 | 654,000.00 |
| Mar 31, 2025 | 654,000.00 |
| Dec 31, 2024 | 709,000.00 |
| Dec 31, 2024 | 709,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 701,000.00 |
| Jun 30, 2024 | 701,000.00 |
| Mar 31, 2024 | 790,000.00 |
| Mar 31, 2024 | 790,000.00 |